The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C02 | Antihypertensives | |
| 3 | C02C | Antiadrenergic agents, peripherally acting | |
| 4 | C02CA | Alpha-adrenoreceptor antagonists | |
| 5 | C02CA01 | Prazosin |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 5 mg |
| Active Ingredient | Description | |
|---|---|---|
| Prazosin |
Prazosin causes a decrease in total peripheral vascular resistance through selective inhibition of postsynaptic alpha-1-adrenoreceptors in vascular smooth muscle. Prazosin has been found to successfully reduce the severity of the signs, symptoms, frequency and duration of attacks, in patients with Raynaud’s disease. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ATODEL Tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
| HYPOVASE Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| MINIPRESS Capsule | FDA, National Drug Code (US) | MPI, US: SPL/Old |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
